JP2024525222A5 - - Google Patents

Info

Publication number
JP2024525222A5
JP2024525222A5 JP2023579857A JP2023579857A JP2024525222A5 JP 2024525222 A5 JP2024525222 A5 JP 2024525222A5 JP 2023579857 A JP2023579857 A JP 2023579857A JP 2023579857 A JP2023579857 A JP 2023579857A JP 2024525222 A5 JP2024525222 A5 JP 2024525222A5
Authority
JP
Japan
Application number
JP2023579857A
Other languages
Japanese (ja)
Other versions
JP2024525222A (ja
JPWO2022271935A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034702 external-priority patent/WO2022271935A1/en
Publication of JP2024525222A publication Critical patent/JP2024525222A/ja
Publication of JPWO2022271935A5 publication Critical patent/JPWO2022271935A5/ja
Publication of JP2024525222A5 publication Critical patent/JP2024525222A5/ja
Pending legal-status Critical Current

Links

JP2023579857A 2021-06-24 2022-06-23 Erk1/2阻害剤併用療法 Pending JP2024525222A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214764P 2021-06-24 2021-06-24
US63/214,764 2021-06-24
PCT/US2022/034702 WO2022271935A1 (en) 2021-06-24 2022-06-23 Erk1/2 inhibitor combination therapy

Publications (3)

Publication Number Publication Date
JP2024525222A JP2024525222A (ja) 2024-07-10
JPWO2022271935A5 JPWO2022271935A5 (https=) 2025-06-24
JP2024525222A5 true JP2024525222A5 (https=) 2025-06-24

Family

ID=84544892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023579857A Pending JP2024525222A (ja) 2021-06-24 2022-06-23 Erk1/2阻害剤併用療法

Country Status (8)

Country Link
US (1) US20240316046A1 (https=)
EP (1) EP4358967A4 (https=)
JP (1) JP2024525222A (https=)
KR (1) KR20240055721A (https=)
CN (1) CN117957001A (https=)
AU (1) AU2022300355A1 (https=)
CA (1) CA3223692A1 (https=)
WO (1) WO2022271935A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200071765A1 (en) * 2016-01-19 2020-03-05 The General Hospital Corporation Cancer treatments and methods of selecting same
JP7234418B2 (ja) * 2019-05-16 2023-03-07 イーライ リリー アンド カンパニー Brafv600e大腸癌の治療に使用するためのerk1/2阻害剤と、braf阻害剤およびegfr阻害剤との三重組み合わせ
CA3158910A1 (en) * 2019-10-28 2021-05-06 Asana Biosciences, Llc Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2

Similar Documents

Publication Publication Date Title
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
JP2024525222A5 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY23963C1 (https=)
BY13135U (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13142U (https=)
BY13170U (https=)
BY13169U (https=)
CN307045493S (https=)
BY13168U (https=)
BY13167U (https=)
BY13166U (https=)
BY13141U (https=)